MedTrace Logo

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004904 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2012-06-04

No results posted yet for this study

Summary

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of treated donor stem cell transplantation in treating patients who have hematologic cancer.

Conditions

Interventions

BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

filgrastim

DRUG

cladribine

DRUG

cyclophosphamide

DRUG

etoposide

DRUG

methylprednisolone

DRUG

tacrolimus

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

Sponsors & Collaborators

Principal Investigators

  • Richard K. Burt, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Primary Completion
2000-07-31
Completion
2000-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004904 on ClinicalTrials.gov